Market Overview

Aegerion's JUXTAPID Capsules Approved in Mexico for Treatment of Homozygous Familial Hypercholesterolemia


Aegerion Pharmaceuticals (Nasdaq: AEGR) today announced that the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has approved JUXTAPID as an adjunct treatment to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non-high-density-lipoprotein cholesterol (non-HDL) in patients with homozygous familial hypercholesterolemia (HoFH). In the approval of JUXTAPID, COFEPRIS gave JUXTAPID Recognition as an Orphan Drug.

See full press release

Posted-In: News Guidance FDA Global


Related Articles (AEGR)

View Comments and Join the Discussion!

Partner Center